Scarica l'app Stockscreener
0.9502
8.63%
-0.0898
Dopo l'orario di chiusura:
.95
-0.0002
-0.02%
Precedente Chiudi:
$1.04
Aprire:
$1.05
Volume 24 ore:
318.41K
Relative Volume:
0.04
Capitalizzazione di mercato:
$6.26M
Reddito:
$3,000
Utile/perdita netta:
$-5.76M
Rapporto P/E:
-0.5144
EPS:
-1.8471
Flusso di cassa netto:
$-5.59M
1 W Prestazione:
-10.36%
1M Prestazione:
-20.82%
6M Prestazione:
-51.02%
1 anno Prestazione:
-72.38%
Intervallo 1D:
$0.9363
$1.0557
Intervallo di 1 settimana:
$0.9363
$1.12
Portata 52W:
$0.62
$6.25
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
Nome
Creative Medical Technology Holdings Inc
Settore
Industria
Telefono
480-399-2822
Indirizzo
211 E. OSBORN RD., PHOENIX
Compare CELZ vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
0.9502 | 6.86M | 3,000 | -5.76M | -5.59M | -1.8471 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Creative Medical Technology Holdings Inc Borsa (CELZ) Ultime notizie
EPS Creative Health Tech’s Controlling Shareholder to Sell 22% Stake While Retaining Control - TipRanks
These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism? - Stocktwits
Creative Medical Technology Increases Authorized Shares to 100 Million - Minichart
Creative Medical Expands Authorized Shares and Warrant Exercise - TipRanks
Creative Medical Technology Holdings Inc. (CELZ) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
CELZ Holds Steady at $1.14 as Creative Medical Technology ConsolidatesActive ETF Flow - vinanet.vn
Creative Medical Technology Holdings Inc. (CELZ) Peer Comparison – Compare with Others - Value Research
Creative Medical Technology Holdings Inc. (CELZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
Creative Medical completes Olastrocel trial enrollment as it sets sights on FDA Phase 3 path - Indian Pharma Post
Rest-Of-Europe Exosome Research Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
CELZ Looks 171.4% Overvalued on GF Value™ - GuruFocus
CELZ Looks 142.9% Overvalued on GF Value™ - GuruFocus
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning - The Manila Times
Creative Medical completes enrollment in chronic back pain trial - Investing.com
Creative Medical Technology Holdings Completes Enrollment And Treatment In FDA-Cleared ADAPT Clinical Trial Evaluating CELZ-201 / Olastrocel - marketscreener.com
Creative Medical finishes treating back-pain patients who use opioids - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Creative (CELZ) EPS and Revenue Review: The EPS Result Is Below Expectation on the Day; Market Follow-Through: The Share Price Sheds 1.82% on the DayGuidance Accuracy Score - vinanet.vn
CELZ Q2 2026 Earnings: Wider Loss of -$0.41 per Share Misses Estimates; Stock Falls 1.6%EPS Consistency Score - vinanet.vn
CELZ Q2 2026 Earnings: EPS Miss of -$0.41 Reflects Pre-Revenue Pipeline InvestmentCFO Commentary Report - vinanet.vn
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
CELZ Q2 2026 Earnings: EPS Misses by 3.07% as Pre-Revenue Losses Persist; Stock Climbs 8.75%Cash Flow Report - vinanet.vn
Creative Medical Technology Holdings Inc (CELZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CELZ Jumps As New Diabetes Patent Fuels Volatile Rally - StocksToTrade
Creative Medical Technology | DEF 14A: Definitive information statements - Moomoo
Creative Medical net loss widens 22.5% to $1.51 million in Q2 2026 - Bitget
Creative Medical Technology Holdings, Inc. (CELZ) stock price, news, quote and history - Yahoo Finance Singapore
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. 2026: Revenue $0 Net income ($1.51M), EPS ($0.41) — 10-Q Summary - TradingView
Creative Medical Technology (NASDAQ: CELZ) Q2 loss, cash rises to $8.7M - Stock Titan
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Top Microcaps CELZ, PRSO, HCWC, TOON: Shorted Stocks to Watch in August 2026 - FinancialContent
Which stocks have an unusual volume on Friday? - ChartMill
Creative Medical Technology Holdings Inc (CELZ) Stock News Today - TradingKey
$Creative Medical Technology (CELZ.US)$ 小赚 - Moomoo
$Creative Medical Technology (CELZ.US)$ sky is so clear and the sun is out 🌄 - Moomoo
CELZ Stock Jumps As New Diabetes Patent Fuels Momentum - stockstotrade.com
$Creative Medical Technology (CELZ.US)$ 🫣 - Moomoo
$Creative Medical Technology (CELZ.US)$ double dipped😋 - Moomoo
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Creative Medical Technology Stock Surges After Key Patent Win - Benzinga
Thursday's session: most active stocks - ChartMill
Medical Stocks To ConsiderAugust 6th - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Creative Medical receives patent allowance for diabetes exosome tech By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings Shares Surge as Traders Appear to Latch Onto Earlier Pipeline Updates and a Tiny-float Setup - Moomoo
Creative Medical receives patent allowance for diabetes exosome tech - Investing.com
Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy - Yahoo Finance
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms - marketscreener.com
Exosome application gets U.S. allowance to target Type 1 diabetes autoimmunity - Stock Titan
Creative Medical Technology Holdings Inc Azioni (CELZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):